SCHEMBL1925544

SCHEMBL1925544

CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)c2)c(=O)c1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 14/20 0.67
CHEK1 O14757 3/20 0.67
PLK4 O00444 2/20 0.67
ROCK2 O75116 2/20 0.67
CHEK2 O96017 2/20 0.67
PIM1 P11309 2/20 0.67
GSK3A P49840 2/20 0.67
GSK3B P49841 2/20 0.67
ROCK1 Q13464 2/20 0.67
PLK3 Q9H4B4 2/20 0.67
SGK1 O00141 1/20 0.67
MAPK13 O15264 1/20 0.67
PDPK1 O15530 1/20 0.67
JAK2 O60674 1/20 0.67
FYN P06241 1/20 0.67
CSF1R P07333 1/20 0.67
MET P08581 1/20 0.67
FLT1 P17948 1/20 0.67
FGFR3 P22607 1/20 0.67
MARK3 P27448 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1927130 0.91 PLK1 (0.67) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL1927076 0.80 PLK1 (1.00) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL1926450 0.74 PLK1 (0.86) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL4371766 0.73 MAPKAPK2 (0.91) PLK1ROCK2CHEK2GSK3AGSK3B
SCHEMBL1926533 0.71 PLK1 (1.00) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL1926622 0.70 PLK1 (0.82) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL1926261 0.70 PLK1 (0.47) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL1926528 0.70 PLK1 (1.00) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL1926267 0.69 PLK1 (0.78) PLK1CHEK1PLK4ROCK2CHEK2
SCHEMBL4365656 0.68 FLT4 (0.65) CHEK1PLK4ROCK2CHEK2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES PLK1, PLK2, BUB1B PLK1 1/4885CHEK1 10/4885PLK4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.